[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.218.90. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1993

Adventures in HemostasisDesmopressin in Cardiac Surgery

Author Affiliations

From Beth Israel Hospital (Drs Salzman and Ware), Boston University School of Medicine (Dr Weinstein), Brigham & Women's Hospital (Dr Reilly), and Harvard Medical School (Drs Salzman, Ware, and Reilly), Boston, Mass.

Arch Surg. 1993;128(2):212-217. doi:10.1001/archsurg.1993.01420140089014
Abstract

• Desmopressin acetate (1-deamino-8-D-arginine vasopressin [DDAVP]) improves hemostasis in hemophilia A and von Willebrand's disease and in some platelet disorders. In complex cardiac operations, excluding simple coronary artery bypass graft procedures, we found that desmopressin reduced blood loss by 40% and the need for transfusion by 34%. Conflicting reports followed. Future trials should emphasize patients with excessive bleeding. A possible postdesmopressin prothrombotic state was studied after hip replacement surgery. The incidence of deep vein thrombosis associated with warfarin sodium therapy was the same as that associated with desmopressin plus warfarin therapy. No desmopressin-induced thrombotic tendency was detected. A trend toward reduced blood loss with desmopressin was not significant. During cardiac catheterization, the plasma von Willebrand factor level was correlated with hemodynamic variables, including pulmonary vascular resistance, pulmonary arterial pressure, and (inversely) with cardiac index, von Willebrand factor concentration was highest in mitral stenosis. The relationship of these factors to the response to desmopressin remains to be defined.

(Arch Surg. 1993;128:212-217)

×